New Recommendations Add Pneumococcal Conjugate Vaccine for Adults Age group 65 Years and Old Specialists also stressed the need for vaccination against pneumococcal disease, which can strike any moment of the year, but also can be considered a deadly complication of influenza. Pneumococcal bacteria result in a severe kind of pneumonia, along with meningitis, blood poisoning and other infections. Based on latest data showing added protection against pneumococcal disease, CDC today published new recommendations adding a second type of pneumococcal vaccine for adults age group 65 years and older. These adults should 1st receive one dosage of pneumococcal conjugate vaccine and one dose of pneumococcal polysaccharide vaccine, six to 12 months later ideally.Their use has received FDA approval to take care of severe graft-versus-host disease in children recently. The existing study was made to investigate MSCs’ therapeutic potential in a style of multiorgan autoimmune disease. The researchers used a stress of mice when a genetic mutation qualified prospects to insufficiency in regulatory T cells, which suppress the experience of self-reactive immune cells, leading to overpowering autoimmune disease. The mice had been treated with infusions of either MSCs or regulatory T cells, and seven days later the researchers examined the consequences on cells from the pancreas, the liver and the distal ileum – the low end of the tiny intestine – which are often attacked by autoimmune reactions.